Jared Simmons shares an episode from his podcast, What is Innovation. In this episode, he interviews William A. Lumpkin, Head of New Products Strategy & Business Development for Alexion, Astra Zeneca Rare Disease Business Unit. Will shares how innovation works within the pharmaceutical industry and how marketing and science differs especially in commercialization. EPISODE SUMMARY William A. Lumpkin is Head of New Products Strategy & Business Development for Alexion, Astra Zeneca Rare Disease Business Unit. Will shares how innovation works…

Umbrex is pleased to welcome Marco Berizzi.  Marco acted as Chief Financial Officer within pharmaceutical and medical device space and as Head of Business Solutions for a company developing business intelligence, advanced analytics and planning platforms in Switzerland since 2013. Prior to this, he spent almost six years in Bain & Company, Italy accomplishing business due-diligences underlying private equity transactions, serving financial institutions customers within corporate banking & risk management projects and dealing with business improvements & BPR projects in…

Umbrex is pleased to welcome Vlad Sumarokov. Vlad spent three years with BCG and has been running his own consulting practice since 2012. Prior to BCG, Vlad spent over a decade in the technology field across multiple industries. In his practice, Vlad provides his expertise to operationalizing large transformation efforts within Pharma and Med Devices industry as well as to organizations seeking to accelerate their innovation agenda via external partnerships. Vlad lives in Portland, OR with his wife and three…

Umbrex is pleased to welcome Andrew McKee with Headland Strategy Group. Andrew has 15 years’ experience in biotechnology, pharmaceuticals, diagnostics, and other healthcare sectors. In his health care work, he specializes in consulting projects for healthcare executives that combine disruptive growth strategy expertise (e.g., disease area strategy, pipeline marketing/commercial evaluations, novel disruptive technologies) with distinctive consulting offerings (e.g., strategic decision-making workshop design and facilitation; qualitative market research with thought leaders). These projects necessarily require Andrew and his team to be…

Umbrex is pleased to welcome Nicholas Gertler with Galen/Atlantica.  Nicholas is co-founder of Galen/Atlantica, a boutique agency that shapes markets and co-creates health. He works with the global pharmaceutical industry across the medicines lifecycle on issues of regulation, access, medical and policy, and with medical foundations addressing complex multi-stakeholder issues. An enduring passion is solving antimicrobial resistance, while a new focus is the proper application of artificial intelligence to medical decision-making. He has co-led a dozen initiatives bringing together senior…

Umbrex is pleased to welcome Yevgeniy Rikhterman.  Yevgeniy Rikhterman spent three years as the Director of Strategy at Herff Jones, a PE owned CPG company. Yevgeniy has experience in creating strategic plans, as well as an evergreen strategic planning processes. Yevgeniy led the strategic planned that helped to maximize the value of Herff Jones during a critical PE transaction. He also led the corporate development, and M&A aspect, and as such has specific experiences that is applicable to mid-size companies…

Umbrex is pleased to welcome Tushar Srivastava. Tushar is an independent strategy consultant who started his consulting career at McKinsey where he spent more than 3.5 years working as a generalist, eventually developing a spike in healthcare and life sciences. He has spent more than 3 years working as an Independent with multiple projects in pharma, life sciences, medical technology and healthcare. Functionally, he is comfortable working on strategy initiatives across R&D, marketing, operations, technology, and pre-sales. He is open…